Behaviorally active doses of the CB1 receptor antagonist SR 141716A increase brain serotonin and dopamine levels and turnover
Authors:
- N.A. DarmaniNDN.A. Darmani
- J.J. JanoyanJJJ.J. Janoyan
- N. KumarNKN. Kumar
- J.L. CrimJCJ.L. Crim
- 1 July 2003
- journal article
- Published by Elsevier in Pharmacology Biochemistry and Behavior
- Vol. 75 (4) , 777-787
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- International Union of Pharmacology. XXVII. Classification of Cannabinoid ReceptorsPharmacological Reviews, 2002
- Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by Δ9-THC and other cannabinoidsPharmacology Biochemistry and Behavior, 2002
- Δ9-Tetrahydrocannabinol and Synthetic Cannabinoids Prevent Emesis Produced by the Cannabinoid CB1 Receptor Antagonist/Inverse Agonist SR 141716ANeuropsychopharmacology, 2001
- Serotonin 5-HT 3 receptor antagonists prevent cisplatin-induced emesis in Cryptotis parva: a new experimental model of emesisJournal of Neural Transmission, 1998
- Physiology of Chemotherapy-Induced Emesis and Antiemetic TherapyDrugs, 1997
- Pharmacology of cannabinoid CB1 and CB2 receptorsPharmacology & Therapeutics, 1997
- Systemic uptake inhibition decreases serotonin release via somatodendritic autoreceptor activationSynapse, 1995
- The CB1 cannabinoid receptor antagonist SR 141716A affects A9 dopamine neuronal activity in the ratNeuroReport, 1995
- Habenula lesions decrease the responsiveness of dorsal raphe serotonin neurons to cocainePharmacology Biochemistry and Behavior, 1994
- SR141716A, a potent and selective antagonist of the brain cannabinoid receptorFEBS Letters, 1994